Back to Search Start Over

Oral RevlimidRPlus Melphalan and Prednisone (R-MP) for Newly Diagnosed Multiple Myeloma.

Authors :
Palumbo, Antonio
Falco, Patrizia
Musto, Pellegrino
Corradini, Paolo
Di Raimondo, Francesco
Rossi, Giuseppe
Giuliani, Nicola
Morabito, Fortunato
Luraschi, Annalisa
Falcone, Antonietta
Omedè, Paola
Gay, Francesca
Avonto, Ilaria
Ambrosini, Maria Teresa
Bringhen, Sara
Zeldis, Jerome
Knight, Robert
Boccadoro, Mario
Petrucci, Maria Teresa
Source :
Blood; November 2005, Vol. 106 Issue: 11 p785-785, 1p
Publication Year :
2005

Abstract

Introduction.Lenalidomide (RevlimidR) is a novel, orally active immunomodulatory drug effective for the treatment of refractory myeloma. In this multicenter trial, we evaluate the potential additive and synergistic effect of the combination RevlimidR, melphalan and prednisone (R-MP).

Details

Language :
English
ISSN :
00064971 and 15280020
Volume :
106
Issue :
11
Database :
Supplemental Index
Journal :
Blood
Publication Type :
Periodical
Accession number :
ejs56858667
Full Text :
https://doi.org/10.1182/blood.V106.11.785.785